Collegium Pharmaceutical (NASDAQ:COLL) Sets New 1-Year Low – Should You Sell?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) shares hit a new 52-week low on Tuesday. The stock traded as low as $21.62 and last traded at $21.6960, with a volume of 250552 shares. The stock had previously closed at $22.63.

Analyst Ratings Changes

A number of brokerages recently commented on COLL. Barclays dropped their price target on shares of Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 19th. Needham & Company LLC lowered their target price on shares of Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Truist Financial initiated coverage on Collegium Pharmaceutical in a research report on Wednesday, September 9th. They set a “buy” rating and a $49.00 target price on the stock. Oppenheimer initiated coverage on Collegium Pharmaceutical in a research report on Wednesday, September 23rd. They issued an “outperform” rating and a $50.00 price target for the company. Finally, Weiss Ratings lowered Collegium Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, September 4th. Six analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $48.71.

Collegium Pharmaceutical Price Performance

The business’s 50-day moving average price is $27.06 and its 200 day moving average price is $31.85. The company has a market capitalization of $710.46 million, a P/E ratio of 17.60, a price-to-earnings-growth ratio of 0.72 and a beta of 0.72. The company has a quick ratio of 0.84, a current ratio of 1.03 and a debt-to-equity ratio of 3.32.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. The business had revenue of $199.88 million for the quarter, compared to analyst estimates of $199.62 million. During the same quarter in the prior year, the firm posted $1.68 EPS. Collegium Pharmaceutical’s revenue was up 6.3% on a year-over-year basis. Analysts anticipate that Collegium Pharmaceutical, Inc. will post 6.21 EPS for the current fiscal year.

Hedge Funds Weigh In On Collegium Pharmaceutical

A number of institutional investors have recently made changes to their positions in COLL. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Collegium Pharmaceutical by 205.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock worth $29,000 after purchasing an additional 427 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Collegium Pharmaceutical by 42.2% in the first quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock worth $47,000 after buying an additional 418 shares during the period. Assetmark Inc. boosted its holdings in Collegium Pharmaceutical by 9.3% during the 1st quarter. Assetmark Inc. now owns 3,923 shares of the specialty pharmaceutical company’s stock valued at $130,000 after acquiring an additional 335 shares during the period. Allworth Financial LP bought a new position in Collegium Pharmaceutical during the 2nd quarter worth approximately $175,000. Finally, EverSource Wealth Advisors LLC increased its stake in Collegium Pharmaceutical by 20.6% in the 1st quarter. EverSource Wealth Advisors LLC now owns 5,035 shares of the specialty pharmaceutical company’s stock worth $167,000 after purchasing an additional 861 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for patients with central nervous system disorders. The company’s portfolio includes treatments for pain and attention deficit hyperactivity disorder (ADHD), with an emphasis on products that address unmet patient and healthcare-provider needs.

Collegium’s pain portfolio includes Xtampza ER, an extended-release oxycodone product designed with abuse-deterrent properties; Nucynta and Nucynta ER, which contain tapentadol and are used to treat certain types of acute and chronic pain; and Belbuca, a buprenorphine buccal film for the management of chronic pain.